OR WAIT null SECS
Investigating IL-5, IL-13, and Tezepelumab Response, with Flavia Hoyte, MD
Hoyte discussed findings from a post hoc analysis of the phase 3 NAVIGATOR study.
A new study has found that tezepelumab seems to be especially efficacious in treating asthma exacerbations in people with both high serum IL-5 and IL-13 levels.
These findings, from a subgroup analysis of the phase 3 NAVIGATOR study (NCT03347279), were presented at the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress, February 28-March 3, in San Diego, California, by Flavia Hoyte, MD, Professor and Director, Allergy & Clinical Immunology Fellowship, Department of Medicine, Division of Allergy & Clinical Immunology, National Jewish Health.
HCPLive spoke with Hoyte to learn more about the analysis and what the investigators found by stratifying participants by IL-5 and IL-13 levels. She discussed implications of the analysis’ findings and theorized that blocking both IL-5 and IL-13 may provide an additive effect in reducing asthma exacerbations. Although these cytokine levels are not usually checked in clinics, Hoyte noted that they may, in the future, be able to be used as biomarkers for response to tezepelumab and other biologics.
“Eventually, I think if the assays can be better understood and better validated for clinical use, then you might be able to use those as a biomarker. And we're always looking for better biomarkers and asthma, so we might be able to use these cytokine levels as a biomarker of who might respond better to one biologic or another,” Hoyte said, although she stressed that they are currently not ready for use in the clinic.
